Clostridium sordellii: Clinical Settings, Diagnostic Clues and Pathogenic Mechanisms

Dennis L. Stevens, M.D., Ph.D.

Veterans Affairs Medical Center, Boise, ID and University of Washington School of Medicine, Seattle, WA

### Introduction & Historical Perspective

- Organism 1<sup>st</sup> isolated by Alfredo Sordellii
- Named it *Bacillus oedematious sporogenes* for the marked tissue edema associated with infections
- Renamed *C. sordellii* in 1937
- Gram positive, spore forming, anaerobic rod
- Thought to be a "virulent" form of *C. bifermentans*
- The 2 species are differentiated on the basis of urease production

# **Case Report #1**

#### Day 1

- 4 yo male; broke arm in fall
- Vitals were normal; arm casted
- **Day 2** 
  - Pain & marked swelling; afebrile, BP 128/82, pulse 150
  - IV cefazolin started; volar fasciotomy performed
- Day 2.5
  - † swelling & pain, BP 108/60, pulse 164, WBC 31,900 with left shift
  - Second trip to OR revealed necrotic muscle & fascia
  - Tissue samples grew *C. sordellii*
- **Day 3** 
  - WBC 41,200, 

     hypotension, 
     tachycardia, metabolic acidosis
  - Pericardiocentesis yielded 75 mls fluid
  - Patient died

### **Case Report #2**

Day 1

21 yo female; vaginal laceration during childbirth Day 5 Perineal pain, difficulty urinating, chills ■ At ER, temp 37.2, BP 96/57, pulse 132, WBC 67K IV gentamicin and clindamycin begun Fasciotomy of vulva; vancomycin added ■ Post-operatively, WBC 123.4K Hypotension, metabolic acidosis, SVT (pulse 170) Copius IV fluids administered Cardiac arrest; patient died ■ Tissues grew *C. sordellii* 

Database Search for Reported *C. sordellii* Infections

- Searched Index Medicus, PubMed and Medline over years 1925-present
- Keywords: Clostridium sordellii, Bacillus sordellii and B. oedematious sporogenes
- Yielded 28 reports describing 41 patients
- Two additional cases reported by us
- Males 49%; female 51%
- Age Range: 17 days 95 years; Mean: 36 yrs

### **Vital Statistics**

|                          | Average Value (range) |                     |  |
|--------------------------|-----------------------|---------------------|--|
|                          | Survivors N=12        | Non-Survivors N=31  |  |
| Age (years)              | 39.3 (12 - 61)        | 34.6 (0 - 95)       |  |
| Gender                   | 0 F/9 M/3 Unk         | 23 F/5 M/3 Unk      |  |
| Temperature (C)          | 37.7 (37 - 38.6)      | 37.3 (35.3 - 41.1)  |  |
| WBCx1000/mm <sup>3</sup> | 18.5 (9.2 - 32.3)     | 75.2 (19.0 - 200.0) |  |

# C. sordellii Infections

|                              | Non-Survivors<br>(N=31) | Survivors<br>(N=12) |
|------------------------------|-------------------------|---------------------|
| Post-partum/OB-GYN infection | 9                       | 0                   |
| MIA                          | 5                       | 0                   |
| Spontaneous abortion         | 2                       | 0                   |
| Injection Drug Users         | 5                       | 5                   |
| Trauma                       | 4                       | 2                   |
| Surgical Procedure           | 4                       | 1                   |
| Other                        | 2                       | 4                   |

| Initial Symptoms of Fatal | Number (of 26)* with |
|---------------------------|----------------------|
| C. sordellii Infections   | Indicated Feature    |
| Onset of illness 2-6 days | 22                   |
| Decreased blood pressure  | 19                   |
| Vomiting                  | 11                   |
| Nausea, dizziness         | 11                   |
| Generalized weakness      | 11                   |
| Diarrhea                  | 5                    |
| Skin blue/ pale           | 3                    |
| Chills                    | 2                    |

\*Only 26/31 fatal cases had enough clinical description to be included in the analysis.

| <b>Clinical Features</b> | Number (of 26) with |
|--------------------------|---------------------|
| C. sordellii Infections  | Indicated Feature   |
| Septic shock             | 23                  |
| Mild infection site pain | 21                  |
| Leukemoid reaction       | 20                  |
| Afebrile                 | 19                  |
| Tachycardia              | 19                  |
| Hemoconcentration        | 16                  |
| Tissue or visceral edema | 16                  |
| Reduced serum protein    | 13                  |
| Metabolic acidosis       | 9                   |
| Decreased platelet count | 7                   |
| RBC and WBC in urine     | 4                   |

| Treatments for<br><i>C. sordellii</i> Infections | No. (of 26) Receiving<br>Indicated Treatment |
|--|--|
| Antibiotics                                      | 25   |
| IV fluids and/or plasma                          | 19   |
| Debridement/amputation                           | 16   |
| ■ Vasopressors, NaHCO <sub>3</sub>               | 12   |
| Steroids, morphine, atropine                     | 11   |
| Supplemental oxygen                              | 5  |

| Microbiology of Fatal             | No. (of 26) with  |  |
|-----------------------------------|-------------------|--|
| C. sordellii Infections           | Indicated Feature |  |
| C. sordellii at site of infection | 26                |  |
| Other organisms at infection site | 19                |  |
| C. sordellii in blood             | 6                 |  |
| Clostridial antigens in localized | 4                 |  |
| blood vessels                     |                   |  |

### Organisms Isolated from Fatal *C. sordellii* Infections (N=31)

- *C. sordellii* (31)
- C. perfringens (6)
- *Escherichia coli* (5)
- Staphylococcus spp. (4)
- Bacteroides spp. (3)
- Group D streptococci (3)
- Staphylococcus aureus (3)
- α hemolytic streptococci (2)
- *Bacillus* spp. (2)
- Enterococcus spp. (2)
- Group G streptococci (2)

- Peptostreptococcus spp. (2)
- Candida albicans (1)
- *Clostridium beijerinckii* (1)
- Coryneform bacteria (1)
- *Enterobacter cloacae* (1)
- Group C streptococci (1)
- *Klebsiella pneumoniae* (1)
- Lactobacillus spp. (1)
- Peptococcus prevotti (1)
- Prevotella loeschii (1)
- Viridans streptococcus (1)

| Autopsy Findings  | No. (of 26) with<br>Indicated Feature |
|---|---------------------------------------|
| <ul> <li>Local necrosis, acute inflammation</li> <li>Marked tissue and/or visceral edema</li> <li>Pericardial, pleural and/or peritoneal effusion</li> <li>Thrombosis of localized blood vessels</li> </ul> | 20<br>19<br>19<br>9                   |
| Neutrophil degeneration at margins of<br>necrotic tissue  | 0                                     |







#### Pathogenesis

Attributable to potent exotoxins

- Lethal toxin (LT) and Hemorrhagic Toxin (HT) have received most attention
- LT and HT are members of a family of Large Clostridial Cytotoxins (LCC) having molecular weights of > 200 kDa.
- Members are highly homologous
- Modify host proteins, such as signaling molecules Rho, Rac, CDC42, by attaching a glycosyl moiety
- The roles of other toxins have not been investigated

| Species                             | Toxins Produced     | Activity   |
|-------------------------------------|---------------------|--|
| <u>Clostridium</u> sordellii        | Lethal Toxin *      | Inhibits signaling G-proteins Rac, Cdc42, Ras and Ra   |
|                                     | Hemorrhagic Toxin * | Inhibits signaling G-proteins Rho, Rac, and Cdc42.   |
|                                     | Hemolysin           | Cholesterol-dependent hemolysin.   |
|                                     | Neuraminidase       | Cleaves sialic acid residues from sialoglycoconjugate  |
|                                     | PLC                 | Hydrolyzes lecithin.   |
|                                     | DNAse               | Potential destruction of host cell nuclei.<br>Splits hyaluronic acid, increasing connective tissue |
|                                     | Hyaluronidase       | permeability.  |
|                                     | Collagenase         | Hydrolyzes collagen and gelatin.   |
| <u>Clostridium</u> <u>difficile</u> | Toxin A *           | Inhibits signaling G-proteins Rho, Rac, and Cdc42  |
|                                     | Toxin B *           | Inhibits signaling G-proteins Rho, Rac, and Cdc42  |
|                                     | Binary Toxin        | Actin-specific ADP-ribosyltransferase  |
|                                     | Hyaluronidase       | Splits hyaluronic acid, increases tissue permeability  |
|                                     | Collagenase         | Hydrolyzes collagen and gelatin.   |
| <u>Clostridium novyi</u>            |                     |  |
| Type A and B                        | α- Toxin *          | Inhibits signaling G-proteins Rho, Rac, and Cdc42.   |
| Type A                              | γ-Phospholipase C   | Hydrolyzes lecithin.   |
| Туре А                              | Hemolysin           | Cholesterol-dependent hemolysin.   |
| Type B and D                        | Tropomyosinase      | Cleaves tropomyosin and myosin.  |
| Type B and D                        | β-Phospholipase C   | Hydrolyzes lecithin; human RBC hemolysin.  |
| Type D                              | Lipase              | Hydrolyzes fats into glycerol and fatty acids.   |

\* Indicates large clostridial cytotoxin.

### Our Investigations into the Mechanisms of Capillary Leak and Leukemoid Reaction

Fractionation of *C. sordellii* exotoxins
Endothelial cell permeability assays
HL-60 proliferation assays
Immune Recognition and Cytokine Induction

#### **Cell Proliferation Assay**

■ Cells: HL-60 – a promyelocytic cell line *C. sordellii* toxins Stationary phase culture of clinical isolate Ammonium sulfate ppt; isoelectric focusing ■ Fractions over pI range 3 – 10 collected HL-60 exposed to fractionated toxins; GM-CSF served as positive proliferation control Cells quantitated by flow cytometry at 5 days

### C. sordellii toxin-induced Myeloid Proliferation



#### Endothelial Cell Permeability Assay

Primary human umbilical vein endothelial cells
Cultured on membrane-lined insert to confluency
Permeability measured by electrical resistance across membrane

Toxins added and resistance measured over 12 hrs

### C. sordellii Exotoxin-Induced Endothelial Permeability



### Innate Immune Recognition and Response to *C. sordellii*

- HEK-293 cells transfected with genes for TLR1, TLR2, TLR4, & TLR6, alone and in combination
- Cells also transfected with MD2, CD14, and ELAM-1-dependent luciferase reporter system
- Washed, log phase, heat-killed, LPS-free organisms added at an optical density at 650 nm of 0.3
- LPS added as a positive TLR4 agonist
- Luciferase activity measured at 4 hr
- Cytokines from PBMC stimulated in parallel were measured by ELISA

### Innate Immune Recognition of the Clostridia



#### Innate Immune Response to the Clostridia



### *C. sordellii* toxin-induced Cytokine Production

PBMC isolated from healthy donors
Stationary phase toxin preparation added for 6 hr
Cytokines in overlying medium measured by protein microarray

# *C. sordellii* toxin-induced Cytokine Production

|        | No Toxin | C. sordellii Toxins | rLT  |
|--------|----------|---------------------|------|
| ΤΝΓα   | -        | +++                 | ++++ |
| IL-1β  | +/-      | ++                  | _    |
| IL-6   | -        | +++                 | ++++ |
| IL-10  | -        | +                   | < ++ |
| GM-CSF | -        | +                   | -    |